NEWS IN BRIEF

MS Pharma acquires Genepharm, expands chronic disease portfolio

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/PrathanChorruangsak)
(Image: Getty/PrathanChorruangsak)

Related tags: Generics, MS Pharma, Genepharm

Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio.

Genepharm develops, manufactures and out-licenses generic pharmaceutical products, focusing on conventional solids, sterile liquid and oncology oral solids, for a client base across 70 countries.

MS Pharma, which operates across the Middle East, Turkey and Africa, will acquire 100% of Genepharm’s shares, while it also announced plans to ‘significantly increase’ Genepharm’s development resources in Athens.

According to MS Pharma, through the acquisition the company aims to expand its geographic footprint and reach more customers in Europe.

In addition, MS Pharma intends to bolster its portfolio with cardiovascular, CNS and oncology products, while it stated that Genepharm's portfolio will be strengthened with sterile injectable products and biotechnology candidates.

According to the agreement, Genepharm’s management will remain with the business. The transaction is expected to close by the end of April 2019. The cost of MS Pharma’s investment was not disclosed.

MS Pharma employs over 2,000 people in its facilities in Algeria, Jordan, Saudi Arabia and Turkey and exports to over 20 countries.

Related news

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more